Between May 13, 2025, and February 19, 2026, Grail executives repeatedly characterized the 140,000-participant NHS-Galleri trial as a robust tool for detecting clinically meaningful early-stage cancers. Throughout this period, management cited positive preliminary data and the performance of the PATHFINDER 2 study to bolster confidence in the trial's trajectory. These assurances suggested the study was adequately powered to deliver a statistically significant reduction in Stage III and IV cancers.
Grail Investors Face Securities Lawsuit After NHS-Galleri Trial Failure
A securities class action lawsuit against Grail, Inc. alleges the company misled investors regarding the efficacy of its NHS-Galleri trial. Following the disclosure that the study failed to meet its primary endpoint of reducing late-stage cancers, shares plummeted 50.55% in a single day, wiping out $51.32 per share.
On February 19, 2026, the company reversed course, admitting the primary endpoint was not observed. Grail executives attributed the failure to an insufficient follow-up period, an admission the lawsuit claims should have been disclosed much earlier. The complaint filed by SueWallSt asserts that internal review of early screening results may have provided management with data suggesting the trial's design was inadequate, yet these risks remained undisclosed. Investors who purchased stock during the class period and suffered losses now face an August 4, 2026, deadline to seek lead plaintiff status in the ongoing litigation.
Comments (0)
No comments yet. Be the first!